Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)
Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)(WS)(ISNHP)
Sponsor: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Terminated
Study stopped for business reasons and not for any safety reasons.
Other terminated trials from InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
More terminations from InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
This observational or N/A phase trial investigates Hyperbilirubinemia and is currently terminated or withdrawn. InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Nov 2019 — Jan 2021 [monthly]
Terminated
-
Jun 2018 — Nov 2019 [monthly]
Terminated
▶ Show 4 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Terminated NA
-
Aug 2017 — Feb 2018 [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.